Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879253 | 0.85 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2LMNAHDAC1PLAU | |
| SCHEMBL30071572 | 0.85 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2LMNAHDAC1PLAU | |
| SCHEMBL940919 | 0.82 | PLAU (0.53) | KDM4ESMN1; SMN2HDAC1PLAUHDAC8 | |
| SCHEMBL29582662 | 0.82 | PLAU (0.53) | KDM4ESMN1; SMN2HDAC1PLAUHDAC8 | |
| SCHEMBL4161973 | 0.82 | MEN1 (0.61) | KDM4EHDAC8HDAC6HDAC2HPGD | |
| SCHEMBL10630917 | 0.80 | LMNA (0.75) | KDM4ESMN1; SMN2LMNAHDAC1CA2 | |
| SCHEMBL11959873 | 0.79 | TAS1R3 (0.59) | KDM4ESMN1; SMN2PLAUHDAC8HDAC6 | |
| SCHEMBL2297552 | 0.79 | TDP1 (0.66) | SMN1; SMN2HDAC1PLAUHDAC8HDAC6 | |
| SCHEMBL11686716 | 0.79 | HPGD (0.53) | KDM4ESMN1; SMN2HDAC1PLAUHDAC8 | |
| SCHEMBL3786490 | 0.79 | SMN1; SMN2 (0.55) | KDM4ESMN1; SMN2PLAUHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| US-8940806-B2 | Polymerizable compositions | BASF SE (DE) | 2015-01-27 | — | — | US | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120041093-A1 | POLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2012-02-16 | — | — | US | disclosed |
| US-4150019-A | COLORFAST, HEAT RESISTANT, MIGRATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041093-A1 | POLYMERIZABLE COMPOSITIONS | H1-10, CBR1, NR1H2 | KDM4E 1897/4885SMN1; SMN2 4025/4885LMNA 3540/4885 |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | KDM4E 2024/4885SMN1; SMN2 165/4885LMNA 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.